Revised outcome of Meeting of Board of Directors held on Friday 13th Feburay 2026 at Pursuant to Regulation 30 of SEBI LODR Regulation 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Johnson Pharmacare's Board met on 13th February 2026 and approved two key changes. First, it appointed M/s VRSK & Associates (Firm Registration No. 011199N), a Delhi-based Chartered Accountancy firm, as the new Statutory Auditor to fill a casual vacancy, with the term running up to the next general meeting. Second, it appointed Ms. Parul Agrawal (DIN: 11268580), a Company Secretary by profession, as an Additional Non-Executive & Independent Director, also effective 13th February 2026. The filings confirm both appointees are eligible and not debarred by SEBI or any other authority, and Ms. Parul Agrawal is not related to any existing Director or Key Managerial Personnel of the company.
These are routine corporate governance changes – the auditor change fills a casual vacancy until the next AGM, and an additional independent director strengthens the board's composition. Neither decision is expected to materially affect the stock price or shareholders' value in the short term.